SUNTO. -I nanovettori rivestono grande interesse per le loro potenzialità in campo terapeutico e diagnostico, come sistemi per veicolare farmaci e per l'imaging medicale. Le loro particolari caratteristiche ne consentono il passaggio attraverso le barriere biologiche e l'accumulo nei siti bersaglio, garantendo inoltre la protezione delle molecole caricate e la modulazione del loro rilascio. Per somministrare nanovettori in maniera efficace e sicura è ovviamente necessario valutarne il possibile effetto citotossico, ma è anche essenziale chiarire i meccanismi di internalizzazione, il traffico intracellulare, le relazioni con gli organuli e la persistenza all'interno della cellula dei nanoparticolati, con particolare attenzione alle loro vie degradative. La microscopia è particolarmente idonea per descrivere le interazioni dei nanovettori con la membrana cellulare e il loro destino intracellulare dopo l'internalizzazione. Nanoparticelle legate a fluorocromi possono essere osservate in microscopia a fluorescenza convenzionale e confocale, mentre l'elevata risoluzione della microscopia elettronica a trasmissione consente di rivelare le fini relazioni dei nanovettori con le strutture subcellulari. In questo articolo sono riassunti alcuni studi condotti utilizzando tecniche microscopiche per valutare le proprietà di nanoparticelle destinate a scopi terapeutici e diagnostici. *** ABSTRACT. -Nanovectors are receiving great attention for their potential in therapeutic and diagnostic applications as innovative systems for drug delivery and medical imaging. Their unique features allow them to pass through the biological barriers, to accumulate at the target sites, to protect the loaded drugs from enzymatic degradation and to modulate their release. To design effective and safe administration procedures of nanovectors it is obviously mandatory to assess their possible cytotoxicity, but it is also essential to elucidate the uptake mechanism(s), the intracellular trafficking pathway, the interactions with cell organelles and the intracellular persistence of nanovectors, paying (*) Department of Neuroscience, Biomedicine and Movement, Anatomy and Histology Section, University of Verona, Italy. E-mail: manuela.malatesta@univr.it particular attention to their degradation routes. Microscopy is especially suitable to describe the interaction of nanocarriers with the cell surface and their intracellular fate following internalization. Fluorochrome-labelled nanoparticles may be observed by conventional and confocal fluorescence microscopy, while the higher resolution of transmission electron microscopy allows to reveal the specific relationships of nanocomposites with the subcellular constituents. This work summarizes some studies performed by different microscopical techniques to evaluate the properties of nanoparticles intended for therapeutic and diagnostic purposes.
INTRODUCTION
Nanovectors are receiving great attention for their potential in therapeutic and diagnostic applications as innovative drug delivery and medical imaging systems. Their unique properties (e.g. small size, large and functionalizable surface area) allow them to pass through the biological barriers (cell membrane, capillary wall, blood brain barrier) and to accumulate at the target sites. Moreover, nanovectors may protect the loaded molecules from enzymatic degradation, prolonging their permanence in the living organism; in addition, the release of the loaded drugs may be modulated, thus improving their sustainability and availability.
Biocompatibility and biodegradability are the basic features of nanovectors designed for biomedical use; it is therefore mandatory to test the behavior of nanovectors in the biological environment. Although nanovectors are intended for administration in vivo, the first step of their evaluation is generally performed in in vitro systems. Evaluating the safety and efficacy of a newly synthesized nanovectors in vitro represents, in fact, a necessary pre-requisite for in vivo experimentation: cultured cells are relatively simple experimental models that enable the analysis of the effects of nanocomposites under strictly controlled conditions, avoiding the complex systemic responses occurring in a living organism; moreover, in vitro experimentation is less expensive than in vivo tests, and allows a remarkable reduction of laboratory animals needed for the following systemic studies.
To design effective and safe administration procedures of nanovectors for therapeutic and diagnostic applications, it is obviously mandatory to assess their possible cytotoxicity after both short and long post-treatment times; in fact, cell necrosis or apoptosis may trigger an inflammatory response in tissues and organs of the patient receiving the nanoparticulate system (Rock and Kono, 2008; Kono et al., 2014) . However, it is also essential to elucidate the uptake mechanism(s), the intracellular trafficking pathway, the interactions with cell organelles and the intracellular persistence of nanovectors, paying particular attention to their degradation route. The intracellular degradation pathway of nanoparticles (NPs) is crucial for estimating the efficacy of a nanocarrier since its entrapment into endosomes may imply a sequestration and a rapid inactivation of the loaded molecules by the lysosomal enzymes (Panyam et al., 2002) .
Microscopy is especially suitable to describe the interaction of NPs with the cell surface and their intracellular fate following internalization. Fluorochrome-labelled NPs may be observed by conventional and confocal fluorescence microscopy, while the higher resolution of transmission electron microscopy allows to reveal the specific relationships of nanocomposites with the subcellular constituents.
Recently, we have also demonstrated that diaminobenzidine photo-oxidation (Maranto, 1982) is especially suitable for unambiguously visualizing fluorescently-labelled NPs at transmission electron microscopy (Malatesta et al., 2012; 2013b; , thus allowing to overcome the limit due to the moderate electron density of many nanovectors (which makes them hardly distinguishable from the intracellular milieu), and to detect their remnants after lytic degradation.
The following chapters describe the information obtained by applying microscopical techniques to evaluate the suitability of different NPs for specific therapeutic and diagnostic purposes.
CHITOSAN NANOPARTICLES FOR THE DELIVERY OF HYPOMETABOLIZING
is a synthetic hypometabolizing opioid (Oeltgen et al., 1988) of potential biomedical interest (Malatesta et al., 2007) . In fact, DADLE is able to significantly prolong the preservation of explanted organs (Oeltgen et al., 1996; Bolling et al., 1997; Su, 2000; Inuo et al., 2007; Tisherman et al., 2013) , to improve cardioprotection (Romano et al., 2004; Yao et al., 2007; Forster et al., 2007; and neuroprotection (Borlongan et al., 2004; Su et al., 2007; Wang et al., 2011; Arrich et al., 2012) under ischemic conditions, and to act as anti-tumour agent (Fichna and Janecka, 2004; Debruyne et al., 2010; Tsai et al., 2010) . Targeting DADLE to the brain would be instrumental to assess its hypometabolising effects in vivo with a consequent decrease in body temperature, which could improve the surgical procedures that imply hypothermy (such as in aortic arch surgery: Yan et al., 2013) . The use in vivo of DADLE is, however, problematic since this molecule is degraded by plasmatic enkephalinases in a few minutes (Shibanoki et al., 1991) and cannot cross the blood brain barrier; encapsulating DADLE into NPs could make its systemic administration more efficient.
Chitosan is a natural cationic polysaccharide widely investigated for the development of drug delivery systems due to its peculiar features such as low immunogenicity and toxicity, easy functionalizability, availability, sustainability and biodegradability (Kumar et al., 2004; Hu et al., 2013; El Kadib et al., 2014; Luo and Wang, 2014) . Chitosan NPs are considered as good carriers for the sustained intracellular delivery of specific molecules since they are able to protect the loaded drugs from lysosomal degradation (Koping-Hoggard et al., 2004; Douglas and Tabrizian, 2005; Serda et al., 2010; Zaki et al., 2011) and to cross diverse biological barriers (Schipper et al., 1997; Peppas and Huang, 2004) , including the blood brain barrier (Karatas et al., 2009; Songjiang and Lixiang, 2009; Wang et al., 2010; Jaruszewski et al., 2012) . These characteristics make chitosan NPs especially promising for DADLE delivery.
With this aim, we investigated the behavior of chitosan NPs inside cultured neuronal cells, and we monitored the intracellular drug release by DADLE-loaded NPs (Malatesta et al., 2012; 2013a) . According to previous observations in other cell types (e.g. Huang et al., 2002; Ma and Lim, 2003; Harush-Frenkel et al., 2007; Park et al., 2010; Zaki et al., 2011) , chitosan NPs proved to be efficiently internalized by endocytosis (Fig. 1a) , to distribute in the cytoplasm accumulating in the perinuclear region (Fig. 1b) , and to escape endosomal degradation as they occur free in the cytosol (Fig. 1c) . However, many NPs were also found inside secondary lysosomes and residual bodies, demonstrating that they finally enter the lytic pathway (Fig. 1d ). When loaded with DADLE, chitosan NPs efficiently release the opioid in the intracellular milieu inducing a fully reversible hypometabolic state which is significantly longer than that observed when DADLE had directly been administered as free molecules in the culture medium. Chitosan NPs were found to persist for weeks inside both the cytoplasm and nucleus (Malatesta et al., 2015) ; since their size does not allow them to pass through the nuclear pore complex (Allen et al., 2000; Labokha and Fassati, 2013) , it is likely that they are entrapped into the nucleus at the end of mitosis, when the nuclear envelope reassembles (Guan et al., 2012) . Although chitosan NPs were never found to make preferential contact with any nuclear component, they could interfere with the overall nuclear functions (e.g. by establishing electrostatic interactions with the nucleic acids, Lai and Lin, 2009) . Therefore, despite the absence of cell death or damage up to two weeks after internalization, further investigation is mandatory on the possible long-term effects of chitosan NP. Malatesta et al., 2012; d, from Malatesta et al., 2015) .
Fig. 1. a. Confocal micrograph of a cell after incubation with fluorescein 5(6)-isothiocyanate labelled chitosan NPs; the cells were previously incubated with the red-fluorescing dye, PKH26 to label the plasma membrane. For several NPs (arrows), green and red fluorescence co-locate, as the result of the endocytotic internalization of part of the plasma membrane. Bar, 10 µm. b-d. Transmission electron micrographs of cells incubated with chitosan NPs; the fine granular, dark reaction product of diaminobenzidine photo-oxidation makes the NPs clearly detectable. b) A NP enclosed in an endosome (arrow) is located very close to the nuclear envelope. N, nucleus. c) A NP (arrow) occurs free in the cytoplasm. d) A dual membrane (thin arrows) partially surrounds a NP (arrow). Bars, 500 nm. (a-c, from

LIPOSOMES, POLYMERIC NANOPARTICLES AND MESOPOROUS SILICA NANOPARTICLES AS DRUG DELIVERY SYSTEMS FOR MUSCLE CELLS
Myotonic dystrophies (DM) are genetically heterogeneous neuromuscular disorders with autosomal dominant inheritance characterized by a variety of pathological features, especially concerning motor functions (Harper, 2001; Meola and Cardani, 2015) . Currently, no disease-modifying therapies are available, and treatments are administered to only manage symptoms. Promising results have been obtained with experimental therapies based on either antisense oligomers or drugs such as pentamidine or actinomycin D (e.g. Warf et al., 2009; Wong et al., 2011; Childs-Disney et al., 2012; Lee et al., 2012; Parkesh et al., 2012; Wheeler et al., 2012; Coonrod et al., 2013; Nguyen et al., 2014; 2015; Pandey et al., 2015; Siboni et al., 2016) . However, these molecules have scarce therapeutic applicability in humans because of their low bioavailability due to enzymatic degradation or their high systemic toxicity. Nanocarriers are able to protect the encapsulated agents from lysis and to allow its sustained release inside the cells: they may, therefore, represent a suitable approach to improve the administration of these therapeutic agents. The nanocarriers must obviously be biocompatible and biodegradable to safely play their action without damaging patient's organism, and this is especially important when they are aimed at delivering therapeutic agents to restore the normal physiological functions in diseased cells that are to be preserved (as the highly differentiated non-cycling cells of skeletal muscles, heart or the central nervous system).
In the attempt to set up an innovative therapeutic strategy based on biocompatible nanocarriers, we tested in cultured cells different biocompatible NPs already known to act as efficient drug-delivery systems. We focused on liposomes, mesoporous silica NPs and polymeric NPs.
Liposomes are attractive vehicles for drug delivery: they are composed of natural phospholipids, consequently being biologically inert and weakly immunogenic, and possess low intrinsic toxicity, high biocompatibility and biodegradability. Further, drugs with different lipophilicities can be encapsulated into liposomes: lipophilic drugs are entrapped in the lipid bilayer while hydrophilic drugs in the aqueous compartment, and the amphiphilic agents are encapsulated both in the lipid bilayer and in the aqueous core (Arpicco et al., 2013; Pedrini et al., 2014) . In our study, we used unconjugated and hyaluronic-acid-conjugated liposomes in order to compare their internalization capability (it is known that hyaluronic acid may increase the uptake efficiency by cells bearing the CD44 receptors, Yu et al., 2013; Li et al., 2015) .
Mesoporous silica NPs have attracted increasing attention due to their peculiar features: they can be easily synthesized and functionalized, show an excellent chemical stability, and are able to load large amounts of molecules whose release can be modulated by varying the size of the pores; moreover, they proved to be highly biocompatible (Chen et al., 2014; Sapino et al., 2015) . Interestingly, both small molecules and oligonucleotides may be encapsulated in mesoporous silica NPs (Peng et al., 2006) . In our study we used amino-mesoporous silica NPs.
Polymeric NPs are made of either natural or synthetic polymers that may be structured as nanospheres (where the loaded drugs are homogeneously dispersed in the matrix) and nanocapsules (where the drug is restricted to the aqueous or oily hollow enclosed in a thin polymeric layer) (Grottkau et al., 2013) . Polymeric NPs are able to improve the solubility and stability of hydrophobic drugs thus reducing their toxicity; this allows a controlled and sustainable release at relatively low doses. Moreover, they demonstrated a high stability in plasma (Stella et al., 2000; 2007a; Lince et al., 2011) . In our study we used poly(methoxypolyethyleneglycol cyanoacrylate-co-hexadecyl cyanoacrylate)-based polymeric NPs.
We first investigated the uptake and intracellular fate of the three nanocarrier types using a human cell line commonly used for basic research as a standardised in vitro system (HeLa cells) (Costanzo et al., 2016b) . All nanocarriers were rapidly internalized by the cells, although the uptake mechanisms and intracellular distribution were characteristic of each nanovector type. Liposomes enter massively the cell, probably by fusion with the plasma membrane (Nazarenus et al., 2014 ) (although a receptor-mediated internalization cannot be excluded), and they undergo rapid degradation at the cell periphery (Fig. 2a) .
Liposomic constituents diffuse into the cytosol and accumulate in lipidic droplets (Fig. 2a') , that are then extruded from the cell surface (a process likely due to excessive uptake of exogenous material).
The rapid intracellular disaggregation of liposomes suggests that they may be suitable for carrying drugs to be rapidly and massively released.
Polymeric NPs enter the cell individually via endocytosis, and occur in the cytoplasm either inside vacuoles or free (Fig. 2b, b' ), demonstrating their ability to escape endosomes. However, most of polymeric NPs re-enter the lytic pathway due to the autophagic process, thus undergoing enzymatic degradation in a few hours. The short intracellular permanence suggests the utilization of these NPs for rapid drug release.
Mesoporous silica NPs are internalized as large clusters via endocytosis and phagocytosis, and remain always enclosed in vacuoles (first endosomes, then secondary lysosomes and finally residual bodies), thus following the intracellular lytic route (Fig. 2c, c' ). However, they persist for long time inside the cell, suggesting their utilization for sustained release of drugs able to cope with the enzymatic degradation and then cross the vacuole membrane.
Based on these promising results, we investigated the effect of these NPs in an established myoblast cell line (C2C12) (Costanzo, 2016a) . In these myoblasts, liposomes and amine-mesoporous silica NPs showed similar results as in HeLa cells, but the cyanoacrylatebased polymeric NPs were found to induce a dramatic increase of cell death and damage.
This strongly suggests that the biological effects of a nanovector may strictly be related to the cell type. Cyanoacrylate-based polymeric NPs were then replaced by poly(lactic-co-glycolic acid) (PLGA) NPs, which proved to be safe (unpublished results). PLGA is, in fact, one of the most successfully used biodegradable polymers because its hydrolysis leads to metabolite monomers (lactic acid and glycolic acid) which are endogenous and easily metabolized via the Krebs cycle, thus leading to a minimal systemic toxicity. Consistently, PLGA is approved by the US FDA and the European Medicine Agency (EMA) in various drug delivery systems for humans (Danhier et al., 2012) .
We are presently investigating liposomes, amine-mesoporous silica NPs and PLGA NPs on primary human myoblasts from skeletal muscle biopsies of healthy and dystrophic subjects, with very encouraging results. Costanzo et al., 2016a) .
Fig. 2. a-c. Confocal micrographs of cells incubated with liposomes (green fluorescence, a), polymeric NPs (red fluorescence, b) and mesoporous silica NPs (green fluorescence, c). All the nanovectors are distributed in the cytoplasm but are absent from the nucleus; note the peripheral location of liposomes. DNA is stained with Hoechst 33342 (blue fluorescence). In a and c the cytoplasm is counterstained with trypan blue (red fluorescence); in b the red fluorescent signal of polymeric NPs has been merged with the brighfield image. Bars: 20 µm. a'-c'. Transmission electron microscopy analysis of the intracellular distribution of liposomes (a'), polymeric NPs (b') and mesoporous silica NPs (c'). a') Liposomes occur free in the cytoplasm and show a loose filamentous periphery. Electron dense fine granular material (arrow) occurs in the cytosol in close proximity to liposomes and lipid droplets (L). Granular material appears distributed also at the periphery (arrowheads) of the lipid droplets (L). b') A polymeric NP is enclosed in an endosome (arrow). c') Large aggregates of mesoporous silica NPs occur at the cell surface (asterisks). Small clusters of NPs are visible inside the cytoplasm, even inside nuclear invaginations (arrows). N, nucleus. Bars, 500 nm (a', b'); 5 µm (c'). (from
MANGANESE-CONTAINING NPS AS A NOVEL CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
Magnetic resonance imaging (MRI) is powerful diagnostic technique that exploits the properties of atom nuclei inside a living body (Cleary and Peters, 2010) . It is a current non-invasive tool in daily clinics, allowing diagnosis to be performed in real time. An intrinsic limitation of MRI is its low sensitivity, which often compromises diagnostic quality. To overcome this disadvantage, different types of contrast agents, which are effective in shortening relaxation times of nearby protons, have been developed and used (Chopra et al., 2012) ; among them, gadolinium (Gd) is currently used in the clinics as MRI contrast agent. Gd-based agents must always be used in chelated form due to the high toxicity of free Gd, although they are not completely free of serious risk (e.g., nephrogenic systemic fibrosis may be induced; Kaewlai and Abujudeh, 2012) . A promising alternative to Gd is represented by manganese (Mn) and its derivatives.
Mn is a trace element physiologically present in the human organism since it is indispensable for several metabolic pathways (e.g., blood coagulation and hemostasis, blood glucose regulation, bone growth, nervous tissue function) (Wedler and Denman, 1984; Patchett et al., 1991; Zwingmann et al., 2004; Miao and St Clair, 2009; Horning et al., 2015) . Mn 2+ is characterized by paramagnetic properties that cause a reduction in T1 relaxation times of water resulting in positive contrast enhancement i.e., a 'bright' signal in T1-weighted MRI images of tissues where Mn 2+ has accumulated. Accordingly, many Mn complexes have been investigated as alternative contrast agents for MRI (Mendonça-Dias et al., 1983; Fornasiero et al., 1987; Nordhoy et al., 2004; Lelyveld et al., 2011) . Further, commercial Mnbased MRI contrast agents have been developed such as, mangafodipir trisodium (Mn-DPDP). However, Mn-based complexes easily dissociate after administration with the formation of free Mn 2+ ; exposure to excess Mn is neurotoxic, and Mn 2+ accumulates most notably in the striatum resulting in the Mn poisoning referred to as 'manganism' (Santamaria, 2008) . This suggests the need for biocompatible and thermodynamically stable Mn compounds.
Thanks to the progress in nanotechnology, Mn can be encapsulated in different types of NPs made of biocompatible materials which are expected to both limit Mn toxicity and become potential positive contrast agents for T1-weighted MRI (Na et al., 2007; Shin et al., 2009; Howell et al., 2013; Lee et al., 2014) . However, the research on Mn-based nano-contrast agents is still at a relatively early stage, and there is a paucity of investigations on in vivo and in vitro toxicity of Mn-based NPs (Li et al., 2013; Xiao et al., 2013; Bellusci et al., 2014; Katsnelson et al., 2015; Yu et al., 2015) .
Our group focused on NPs obtained by thermal decomposition of Mn-oleate complex and then encapsulated in a phospholipidic shell containing also a small amount of polyethylene glycol, thus improving their water solubility, stability, bioavailability and biocompatibility. These NPs are especially interesting since they gave promising results as MRI contrast agents and drug carriers (Howell et al., 2013) . By combining flow cytometry, confocal microscopy and transmission electron microscopy, we explored in vitro their cytotoxicity, internalization kinetics, intracellular distribution and degradation (Costanzo et al., 2016c) .
Our results confirmed the safety of these Mn-containing NPs since the viability assay did not detect alterations after both short (one hour) and long (two days) incubation times. Flow cytometry allowed monitoring the internalization kinetics of NPs: they entered the cells in a few minutes and reached the maximum internalization after one hour exposure, thus demonstrating an excellent uptake efficiency. Fluorescence microscopy and transmission electron microscopy demonstrated that Mn-containing NPs enter the cell probably by fusion with the plasma membrane (Fig. 3a, b) , and remain free in the cytosol, without making contact with cell organelles (Fig. 3c) . It is in fact known that the uptake of hydrophobic nanocomposites may occur by lipid raft-mediated endocytosis, a process that allows to bypass the endolytic pathway thus facilitating the intracellular permanence of the NPs (Lanza et al., 2011) . Interestingly, lipid rafts are typical of numerous tumor cells (Mollinedo and Gajate, 2015; Nicolson, 2015) , thus opening promising perspectives for the use of Mn-containing NPs for diagnostic and therapeutic purposes.
Despite the long intracellular permanence of free Mn-containing NPs, no structural damage of cell components was detected, suggesting that the organic shell is not degraded by the cytosolic enzymes. Finally, the Mn-containing NPs undergo autophagic process, thus entering the lysosomal route and being degraded through a physiological pathway. The long-lasting intracellular per-manence of Mn-containing NPs must be taken into account as a potential risk in the case of multiple administrations as contrast agent, but it may represent an advantage for their use as drug delivery system since it may ensure a sustained release.
Taken together, our in vitro data suggest that Mn-containing NPs may be promisingly considered for therapeutic and diagnostic applications in vivo, as drug carriers or contrast agent for MRI. 
CONCLUSIONS
Microscopical techniques proved to be a powerful approach to investigate in vitro the effects of nanovectors on cell components. By brightfield and fluorescence microscopy, the uptake and distribution of NPs in the whole cell population may be described, while transmission electron microscopy provides highly-resolved images of the NP interaction with the plasma membrane and the subcellular organelles, and of the induced ultrastructural cell damage undetectable at light microscopy. Microscopical analyses are not limited to morphological observation, since the NPs can be detected in association with single molecular components visualized by cytochemical staining or immunocytochemical labelling.
It may be envisaged that this approach in situ will be increasingly applied to precisely elucidate the spatial and functional relationships of nanovectors with specific cell constituents in the attempt to fully understand the interaction mechanisms and the potential risks of NP administration.
